DE60115411D1 - Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten - Google Patents

Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten

Info

Publication number
DE60115411D1
DE60115411D1 DE60115411T DE60115411T DE60115411D1 DE 60115411 D1 DE60115411 D1 DE 60115411D1 DE 60115411 T DE60115411 T DE 60115411T DE 60115411 T DE60115411 T DE 60115411T DE 60115411 D1 DE60115411 D1 DE 60115411D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
compositions
allergic conditions
treating allergic
pgd2 receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60115411T
Other languages
English (en)
Inventor
R Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Application granted granted Critical
Publication of DE60115411D1 publication Critical patent/DE60115411D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
DE60115411T 2000-04-12 2001-04-09 Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten Expired - Lifetime DE60115411D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19664100P 2000-04-12 2000-04-12
PCT/CA2001/000491 WO2001078697A2 (en) 2000-04-12 2001-04-09 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists

Publications (1)

Publication Number Publication Date
DE60115411D1 true DE60115411D1 (de) 2006-01-05

Family

ID=22726224

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60115411T Expired - Lifetime DE60115411D1 (de) 2000-04-12 2001-04-09 Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten

Country Status (8)

Country Link
US (1) US20030055077A1 (de)
EP (1) EP1274457B1 (de)
JP (1) JP2003530426A (de)
AT (1) ATE311200T1 (de)
AU (1) AU2001250206A1 (de)
CA (1) CA2405233A1 (de)
DE (1) DE60115411D1 (de)
WO (1) WO2001078697A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
WO2004087095A2 (es) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Dispositivo osmótico que contiene zafirlukast y un antagonista h1
JP4051398B2 (ja) 2004-03-11 2008-02-20 アクテリオン ファマシューティカルズ リミテッド テトラヒドロピリドインドール誘導体
TW200716093A (en) * 2005-04-28 2007-05-01 Shionogi & Co An antiasthmatic agent containing PGD2 receptor antagonist and leukotriene receptor antagonist
JP5114202B2 (ja) 2005-09-27 2013-01-09 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
MX2012007239A (es) 2009-12-23 2012-10-15 Ironwood Pharmaceuticals Inc Moduladores de crth2.
CA2793324A1 (en) 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. A substituted pyrimidine as a prostaglandin d2 receptor antagonist
MX2012010035A (es) 2010-03-16 2012-10-01 Aventis Pharma Inc Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2.
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN102791689B (zh) 2010-03-22 2014-10-29 埃科特莱茵药品有限公司 3-（杂芳基-氨基）-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途
EA026692B1 (ru) 2010-06-30 2017-05-31 Айронвуд Фармасьютикелз, Инк. Стимуляторы sgc
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
EP2637659B1 (de) 2010-11-09 2016-05-18 Ironwood Pharmaceuticals, Inc. Sgc-stimulatoren
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
EP2762141A4 (de) * 2011-09-29 2015-03-25 Shionogi & Co Arzneimittel zur behandlung von allergischer rhinitis mit einem pgd2-antagonisten und histamin-antagonisten
CN106117194A (zh) 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
KR101418404B1 (ko) * 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014047325A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
ES2911276T3 (es) 2013-03-15 2022-05-18 Cyclerion Therapeutics Inc Estimuladores de sGC
MX2016007522A (es) 2013-12-11 2017-12-15 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
US20160324856A1 (en) 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
CA2939892C (en) 2014-03-17 2020-03-31 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
AU2015233046A1 (en) 2014-03-18 2016-11-03 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
EP3194386A2 (de) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc-stimulatoren
EP3194382B1 (de) 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Pyrazolderivate als sgc-stimulatoren
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN108026093B (zh) 2015-09-15 2021-11-16 爱杜西亚药品有限公司 结晶形式
MA45592A (fr) 2016-07-07 2019-05-15 Ironwood Pharmaceuticals Inc Promédicaments à base de phosphore de stimulateurs de sgc
KR20230074840A (ko) 2016-07-07 2023-05-31 사이클리온 테라퓨틱스, 인크. sGC 자극제의 고체 형태

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
HUP9802678A3 (en) * 1995-06-21 1999-12-28 Shionogi & Co Bicyclic amino derivatives and pgd2 antagonist containing the same
PL191760B1 (pl) * 1996-12-13 2006-06-30 Shionogi & Co Związki, pochodne benzotiofenokarboksyamidu, związki pośrednie, kompozycja farmaceutyczna zawierająca te pochodne oraz lek do leczenia blokady nosa

Also Published As

Publication number Publication date
WO2001078697A2 (en) 2001-10-25
US20030055077A1 (en) 2003-03-20
CA2405233A1 (en) 2001-10-25
WO2001078697A3 (en) 2002-08-01
AU2001250206A1 (en) 2001-10-30
ATE311200T1 (de) 2005-12-15
EP1274457B1 (de) 2005-11-30
EP1274457A2 (de) 2003-01-15
JP2003530426A (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
DE60115411D1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
DE60043308D1 (de) Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
TNSN04001A1 (fr) Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase.
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE60040719D1 (de) Verfahren und Vorrichtung zur Behandlung von Halbleitersubstraten
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
DE60238149D1 (de) Arylsulfonamid-Derivate zur Verwendung als CCR3-Antagonisten bei der Behandlung von inflammatorischen und immunologischen Erkrankungen
DE60120822D1 (de) Meta-Dokument und Verfahren zum Verwalten von Meta-Dokumenten
DE60011918D1 (de) Vorrichtung und verfahren zur lokalen behandlung von wasser
ATE515513T1 (de) Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten
ATE406159T1 (de) Behandlung von hyperlipidämie
DE60124666D1 (de) Verfahren zur hydrierung von conjugierten dienpolymeren und copolymeren
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
ATE371454T1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
DE60232956D1 (de) Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
DE60114027D1 (de) Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
ATE381938T1 (de) Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
ATE352038T1 (de) Kit und verfahren zum nachweis von fäkalen parasiten
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
DE60018707D1 (de) Anti-androgene und verfahren zur behandlung von krankheiten
ATE317268T1 (de) Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis
ATE385789T1 (de) Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen

Legal Events

Date Code Title Description
8332 No legal effect for de